Ascendis Pharma A (ASND) Research & Development (2014 - 2026)
Ascendis Pharma A (ASND) posted Research & Development of -$88.21 million for the quarter ended Jun 30, 2026, compared with -$81.49 million a year earlier.
Powered by 
Analysis
Ascendis Pharma A (ASND) Research & Development (2014 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Research & Development at Ascendis Pharma A was -$326.49 million; for the year ended Dec 31, 2025, it came in at $343.03 million, up 3.2% from the prior year.
- Annual Research & Development shows a five-year compound annual growth rate of 2.0% (years ended Dec 2020 to Dec 2025).
- In prior years, Ascendis Pharma A's Research & Development was $332.28 million in the year ended Dec 31, 2024, -$447.24 million in the year ended Dec 31, 2023, $400.11 million in the year ended Dec 31, 2022 (+18.2%) and $338.46 million in the year ended Dec 31, 2021 (+8.8%).
- Quarterly Research & Development has run from a low of -$91.1 million in the quarter ended Mar 31, 2025 to a high of $121.31 million in the quarter ended Sep 30, 2023 over five years.
- The strongest year-over-year quarter for Research & Development in the past five years was the quarter ended Dec 31, 2022, with growth of 47.6%; the weakest was the quarter ended Dec 31, 2021, with a decline of 85.9%.
- According to Business Quant data, Research & Development for the three prior quarters was -$69.13 million (quarter ended Mar 31, 2026), -$90.97 million (quarter ended Dec 31, 2025) and -$78.19 million (quarter ended Sep 30, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Ascendis Pharma A | 14.26 Bn | 10.50 Bn | 362.22 Mn | -88.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -88.21 Mn |
| Mar 31, 2026 | -69.13 Mn |
| Dec 31, 2025 | -90.97 Mn |
| Sep 30, 2025 | -78.19 Mn |
| Jun 30, 2025 | -81.49 Mn |
| Mar 31, 2025 | -91.10 Mn |
| Dec 31, 2024 | -84.73 Mn |
| Sep 30, 2024 | -80.77 Mn |
| Jun 30, 2024 | 89.90 Mn |
| Mar 31, 2024 | 76.79 Mn |
| Dec 31, 2023 | 97.78 Mn |
| Sep 30, 2023 | 121.31 Mn |
| Jun 30, 2023 | 114.36 Mn |
| Mar 31, 2023 | 113.90 Mn |
| Dec 31, 2022 | 110.82 Mn |
| Sep 30, 2022 | 98.24 Mn |
| Jun 30, 2022 | 96.44 Mn |
| Mar 31, 2022 | 93.37 Mn |
| Dec 31, 2021 | 75.10 Mn |
| Sep 30, 2021 | 69.30 Mn |
API Access
Ascendis Pharma A Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=ASND&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "ASND", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=ASND&period=max&api_key=YOUR_API_KEY");
const data = await res.json();